ArticleCureus2025
Prognostic Factors and Optimal Empiric Therapy for Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales Bacteremia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Bloodstream infections (BSIs) caused by extended-spectrum β-lactamase-producingEnterobacterales (ESBL-E) are associated with increased morbidity and mortality, yet the optimal empiric treatment strategy remains uncertain. We aimed to identify prognostic factors for early clinical response and 30-day mortality in patients with ESBL-E bacteremia and to evaluate the impact of the appropriateness of empiric antimicrobial therapy. Methods We conducted a retrospective cohort study at a 916-bed tertiary care hospital in Tokyo, Japan, including all patients with ESBL-E bacteremia between April 2018 and March 2023. Clinical, microbiological, and therapeutic data were extracted from electronic medical records. Independent variables were selected based on prior literature, including age, sex, Charlson Comorbidity Index (CCI), quick sequential organ failure assessment (qSOFA) score, infection setting, invasive device use, C-reactive protein (CRP) level, and appropriateness of empiric antimicrobial therapy. Logistic regression was used to identify predictors of clinical improvement within 72 hours and 30-day all-cause mortality. Results A total of 138 patients were included, with a median age of 72.7 years; 83% of infections were caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.